News & Updates

Zoledronic acid fails to ZAP pain, structural progression in knee OA

21 May 2020 by

Annual infusions of zoledronic acid did not significantly cut pain and cartilage volume loss in patients with symptomatic knee osteoarthritis (OA) and bone marrow lesions, the ZAP2* trial has shown.

Zoledronic acid fails to ZAP pain, structural progression in knee OA

21 May 2020

Riociguat: beneficial for cutaneous systemic sclerosis patients?

20 May 2020 by

The sGC* stimulator riociguat did not offer substantial benefit for patients with early, diffuse cutaneous systemic sclerosis (SSc) who are at high risk for skin fibrosis progression; however, other potential efficacy signals should not be discounted, the phase IIb RISE-SSc** trial has shown.

Riociguat: beneficial for cutaneous systemic sclerosis patients?

20 May 2020

High-intensity interval training eases musculoskeletal pain in sedentary diabetics

19 May 2020

Eight-weeks of high-intensity training that combines aerobic and resistance exercises confer benefits for musculoskeletal pain, but not neuropathic symptoms, in sedentary patients with type 2 diabetes (T2D), as shown in a study.

High-intensity interval training eases musculoskeletal pain in sedentary diabetics

19 May 2020

Tanezumab effective for hip, knee osteoarthritis

18 May 2020 by

Use of the nerve growth factor (NGF) inhibitor tanezumab led to significant improvements in pain and physical function in patients with moderate-to-severe osteoarthritis (OA) of the hip and knee who have intolerance or insufficient response to standard analgesics*, a phase III study has shown.

Tanezumab effective for hip, knee osteoarthritis

18 May 2020

Ixekizumab COASTs through r-axSpA with sustained efficacy, safety

13 May 2020 by

Two phase III trials reflect the sustained efficacy and safety of the bDMARD* ixekizumab in bDMARD-naïve (COAST-V) or TNFi**-experienced (COAST-W) adults with active radiographic axial spondyloarthritis (r-axSpA), also known as ankylosing spondylitis (AS).

Ixekizumab COASTs through r-axSpA with sustained efficacy, safety

13 May 2020

Switching to second, third TNFi tied to lower drug survival, response rates in PsA patients

13 May 2020

Patients with axial and peripheral psoriatic arthritis (PsA) who switch to a second or third tumour necrosis factor inhibitor (TNFi) have significantly lower drug survival and response rates, a recent study has found.

Switching to second, third TNFi tied to lower drug survival, response rates in PsA patients

13 May 2020

Medication use, age up caesarean delivery risk in women with ankylosing spondylitis

12 May 2020

Maternal age and disease-related factors contribute to the increased rate of caesarean delivery in women with ankylosing spondylitis (AS), suggests a recent study.

Medication use, age up caesarean delivery risk in women with ankylosing spondylitis

12 May 2020

Golimumab-methotrexate combo shows potential in psoriatic dactylitis

11 May 2020 by

The addition of the TNFi* golimumab to the conventional synthetic DMARD** methotrexate (MTX) led to greater clinical improvements in dactylitis activity in patients with psoriatic arthritis (PsA) compared with MTX monotherapy, results of the GO-DACT*** trial have shown.

Golimumab-methotrexate combo shows potential in psoriatic dactylitis

11 May 2020

Upadacitinib a promising treatment option in selected RA

07 May 2020 by

The oral Janus Kinase (JAK) inhibitor upadacitinib appears to be useful in the treatment of rheumatoid arthritis (RA) patients with inadequate response to conventional synthetic disease-modifying antirheumatic drugs, with the 15-mg dose having the most favourable risk-benefit profile, according to data from the phase IIb/III SELECT-SUNRISE study.

Upadacitinib a promising treatment option in selected RA

07 May 2020

$Fenebrutinib effective against refractory rheumatoid arthritis$

Fenebrutinib effective against refractory rheumatoid arthritis

07 May 2020

The Bruton’s tyrosine kinase inhibitor fenebrutinib is safe and effective in the treatment of refractory rheumatoid arthritis, with the effect comparable to that observed with adalimumab, according to the results of a phase II study.

Fenebrutinib effective against refractory rheumatoid arthritis

07 May 2020

News & Updates

Filter by Specialty:

Specialty:

Zoledronic acid fails to ZAP pain, structural progression in knee OA

Zoledronic acid fails to ZAP pain, structural progression in knee OA

Riociguat: beneficial for cutaneous systemic sclerosis patients?

Riociguat: beneficial for cutaneous systemic sclerosis patients?

High-intensity interval training eases musculoskeletal pain in sedentary diabetics

High-intensity interval training eases musculoskeletal pain in sedentary diabetics

Tanezumab effective for hip, knee osteoarthritis

Tanezumab effective for hip, knee osteoarthritis

Ixekizumab COASTs through r-axSpA with sustained efficacy, safety

Ixekizumab COASTs through r-axSpA with sustained efficacy, safety

Switching to second, third TNFi tied to lower drug survival, response rates in PsA patients

Switching to second, third TNFi tied to lower drug survival, response rates in PsA patients

Medication use, age up caesarean delivery risk in women with ankylosing spondylitis

Medication use, age up caesarean delivery risk in women with ankylosing spondylitis

Golimumab-methotrexate combo shows potential in psoriatic dactylitis

Golimumab-methotrexate combo shows potential in psoriatic dactylitis

Upadacitinib a promising treatment option in selected RA

Upadacitinib a promising treatment option in selected RA

Fenebrutinib effective against refractory rheumatoid arthritis

Fenebrutinib effective against refractory rheumatoid arthritis